Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor

International Journal of Obesity

Volumn 40, Issue 9, 2016, Pages 1424-1434

  Hoang Yen Tran, D ^a   Hoang Ngoc Tran, D ^a   Mattai, S A ^a   Sallam, T ^a   Ortiz, C ^a   Lee, E C ^a   Robbins, L ^c   Ho, S ^a   Lee, J E ^a   Fisseha, E ^a   Shieh, C ^a   Sideri, A ^a   Shih, D Q ^c   Fleshner, P ^c   McGovern, D P B ^c   Vu, M ^c   Hing, T C ^a   Bakirtzi, K ^a   Cheng, M ^a   Su, B ^a   Law, I ^a   Karagiannides, I ^a   Targan, S R ^c   Gallo, R L ^b   Li, Z ^a   Koon, H W ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CD36 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; STREPTOZOCIN; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY MASS; CELL DIFFERENTIATION; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FAT MASS; FATTY LIVER; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIVER CELL; MALE; MESENTERIC FAT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; 3T3-L1 CELL LINE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPLICATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; IMPAIRED GLUCOSE TOLERANCE; LIVER; METABOLISM; PATHOLOGY;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CD36 ANTIGENS; CELL DIFFERENTIATION; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; PREDIABETIC STATE;

EID: 84974698846     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2016.90     Document Type: Article

References (38)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311: 806-814.
2. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff 2009; 28: w822-w831.
3. Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol 2016; 12: 15-28.
4. Chen L, Chen R, Wang H, Liang F. Mechanisms linking inflammation to insulin resistance. Int J Endocrinol 2015; 2015: 508409.
5. Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G, Meshkani R. Molecular and cellular mechanisms linking inflammation to insulin resistance and beta-cell dysfunction. Transl Res 2016; 167: 228-256.
6. Ho S, Pothoulakis C, Koon HW. Antimicrobial peptides and colitis. Curr Pharm Des 2013; 19: 40-47.
7. Rivas-Santiago B, Trujillo V, Montoya A, Gonzalez-Curiel I, Castaneda-Delgado J, Cardenas A et al. Expression of antimicrobial peptides in diabetic foot ulcer. J Dermatol Sci 2012; 65: 19-26.
8. Gonzalez-Curiel I, Castaneda-Delgado J, Lopez-Lopez N, Araujo Z, Hernandez-Pando R, Gandara-Jasso B et al. Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus. Hum Immunol 2011; 72: 656-662.
9. Park HY, Kim JH, Jung M, Chung CH, Hasham R, Park CS et al. A long-standing hyperglycaemic condition impairs skin barrier by accelerating skin ageing process. Exp Dermatol 2011; 20: 969-974.
10. Carretero M, Escamez MJ, Garcia M, Duarte B, Holguin A, Retamosa L et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol 2008; 128: 223-236.
11. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver. Epidemiology and natural history. Rev Recent Clin Trials 2014; 9: 126-133.
12. Yoon HJ, Cha BS. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol 2014; 6: 800-811.
13. Kobyliak N, Abenavoli L. The Role of liver biopsy to assess non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9: 159-169.
14. Zezos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 15532-15538.
15. Karagiannides I, Kokkotou E, Tansky M, Tchkonia T, Giorgadze N, O'Brien M et al. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci USA 2006; 103: 5207-5212.
16. Karagiannides I, Bakirtzi K, Kokkotou E, Stavrakis D, Margolis KG, Thomou T et al. Role of substance P in the regulation of glucose metabolism via insulin signalingassociated pathways. Endocrinology 2011; 152: 4571-4580.
17. Karagiannides I, Thomou T, Tchkonia T, Pirtskhalava T, Kypreos KE, Cartwright A et al. Increased CUG triplet repeat-binding protein-1 predisposes to impaired adipogenesis with aging. J Biol Chem 2006; 281: 23025-23033.
18. Hara T, Kimura I, Inoue D, Ichimura A, Hirasawa A. Free fatty acid receptors and their role in regulation of energy metabolism. Rev Physiol Biochem Pharmacol 2013; 164: 77-116.
19. Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY et al. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 2009; 24: 1658-1668.
20. Turcotte LP, Raney MA, Todd MK. ERK1/2 inhibition prevents contraction-induced increase in plasma membrane FAT/CD36 content and FA uptake in rodent muscle. Acta Physiol Scand 2005; 184: 131-139.
21. Pop-Busui R, Ang L, Holmes C, Gallagher K, Feldman EL. Inflammation as a therapeutic target for diabetic neuropathies. Curr Diab Rep 2016; 16: 29.
22. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785-791.
23. Bonen A, Campbell SE, Benton CR, Chabowski A, Coort SL, Han XX et al. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc Nutr Soc 2004; 63: 245-249.
24. Martin C, Chevrot M, Poirier H, Passilly-Degrace P, Niot I, Besnard P. CD36 as a lipid sensor. Physiol Behav 2011; 105: 36-42.
25. Christiaens V, Van Hul M, Lijnen HR, Scroyen I. CD36 promotes adipocyte differentiation and adipogenesis. Biochim Biophys Acta 2012; 1820: 949-956.
26. Pinheiro da Silva F, Gallo RL, Nizet V. Differing effects of exogenous or endogenous cathelicidin on macrophage toll-like receptor signaling. Immunol Cell Biol 2009; 87: 496-500.
27. Bost F, Aouadi M, Caron L, Even P, Belmonte N, Prot M et al. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 2005; 54: 402-411.
28. Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, Garcia-Mediavilla MV, Fernandez-Bermejo M, Lozano-Rodriguez T et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 2011; 60: 1394-1402.
29. Clugston RD, Yuen JJ, Hu Y, Abumrad NA, Berk PD, Goldberg IJ et al. CD36-deficient mice are resistant to alcohol-and high-carbohydrate-induced hepatic steatosis. J Lipid Res 2014; 55: 239-246.
30. Jiao P, Feng B, Li Y, He Q, Xu H. Hepatic ERK activity plays a role in energy metabolism. Mol Cell Endocrinol 2013; 375: 157-166.
31. Andersen H. Motor dysfunction in diabetes. Diabetes Metab Res Rev 2012; 28: 89-92.
32. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications 2010; 24: 354-360.
33. Krause MP, Riddell MC, Hawke TJ. Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms. Pediatr Diabetes 2011; 12: 345-364.
34. Cotter MA, Cameron NE, Robertson S, Ewing I. Polyol pathway-related skeletal muscle contractile and morphological abnormalities in diabetic rats. Exp Physiol 1993; 78: 139-155.
35. Cameron NE, Cotter MA, Robertson S. Changes in skeletal muscle contractile properties in streptozocin-induced diabetic rats and role of polyol pathway and hypoinsulinemia. Diabetes 1990; 39: 460-465.
36. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997; 40: 271-281.
37. Sacerdote P, Franchi S, Trovato AE, Valsecchi AE, Panerai AE, Colleoni M. Transient early expression of TNF-alpha in sciatic nerve and dorsal root ganglia in a mouse model of painful peripheral neuropathy. Neurosci Lett 2008; 436: 210-213.
38. Zhang LJ, Guerrero-Juarez CF, Hata T, Bapat SP, Ramos R, Plikus MV et al. Innate immunity. Dermal adipocytes protect against invasive Staphylococcus aureus skin infection. Science 2015; 347: 67-71.